Evidence map›Paper›PMID 33084938›Full record

Observational studyJournal of neurology2021

Dimitri Renard, Laurent Collombier, Sabine Laurent-Chabalier, Thibault Mura, Anne Le Floch, Hassan El Fertit, Eric Thouvenot, Jean Sebastien Guillamo

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04306484 (18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04306484 completednot on this map

18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions

TypeobservationalSponsorCentre Hospitalier Universitaire de NīmesRan2020 to 2020Enrolled74ConditionsBrain TumorArmsFDOPA-TEP
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Manufacturing 6-[Organic letters · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Dimitri RenardDepartment of Neurology, CHU Nîmes, University Montpellier, Nîmes, France. dimitrirenard@hotmail.com.
Laurent CollombierDepartment of Nuclear Medicine, CHU Nîmes, University Montpellier, Nîmes, France.
Sabine Laurent-ChabalierDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, CHU Nîmes, University Montpellier, Nîmes, France.
Thibault MuraDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, CHU Nîmes, University Montpellier, Nîmes, France.
Anne Le FlochDepartment of Neurology, CHU Nîmes, University Montpellier, Nîmes, France.
Hassan El FertitDepartment of Neurosurgery, CHU Nîmes, University Montpellier, Nîmes, France.
Eric ThouvenotDepartment of Neurology, CHU Nîmes, University Montpellier, Nîmes, France.
Jean Sebastien GuillamoDepartment of Neurology, CHU Nîmes, University Montpellier, Nîmes, France.
Université de Nîmes · FRCentre Hospitalier Universitaire de Nîmes · FRInstitut de Génomique Fonctionnelle · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction3,4-Dihydroxy-6-[

methodsWe retrospectively analysed consecutively recruited patients with suspected primary brain tumor (based on clinical and magnetic resonance imaging findings) referred for FDOPA-PET in our centre between November 2013 and June 2019 (n = 74). FDOPA-PET parameters (maximum and mean lesion standardised uptake values [SUV] and ratios comparing lesion with different background uptake SUV) and thresholds were evaluated to determine which offered optimal discrimination between pseudotumoral and tumoral lesions.

resultsOverlapping PET values were observed between pseudotumoral (n = 26) and tumoral (n = 48) lesion, particularly for low-grade tumors. Based on receiver operating characteristic (ROC) analyses, the optimal PET parameters to discriminate pseudotumoral from tumoral lesions were SUV

conclusionFDOPA-PET uptake should be interpreted with caution in patients with suspected primary brain tumor, especially in patients showing low or intermediate SUV values and ratios. CLINICAL TRIAL REGISTRATION-URL: https://www.clinicaltrials.gov . Unique identifier: NCT04306484.

Indexed as

Brain NeoplasmsDihydroxyphenylalanineBrainHumansPositron-Emission TomographyRadiopharmaceuticalsRetrospective StudiesDihydroxyphenylalanineRadiopharmaceuticals3,4-dihydroxy-6-[18f]-fluoro-l-phenylalanineFDOPAPETPseudotumorTumor

Identifiers

PMID33084938
OpenAlexW3094442262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.